Dermatofibrosarcoma protuberans

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search

WikiDoc Resources for

Dermatofibrosarcoma protuberans

Articles

Most recent articles on Dermatofibrosarcoma protuberans

Most cited articles on Dermatofibrosarcoma protuberans

Review articles on Dermatofibrosarcoma protuberans

Articles on Dermatofibrosarcoma protuberans in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Dermatofibrosarcoma protuberans

Images of Dermatofibrosarcoma protuberans

Photos of Dermatofibrosarcoma protuberans

Podcasts & MP3s on Dermatofibrosarcoma protuberans

Videos on Dermatofibrosarcoma protuberans

Evidence Based Medicine

Cochrane Collaboration on Dermatofibrosarcoma protuberans

Bandolier on Dermatofibrosarcoma protuberans

TRIP on Dermatofibrosarcoma protuberans

Clinical Trials

Ongoing Trials on Dermatofibrosarcoma protuberans at Clinical Trials.gov

Trial results on Dermatofibrosarcoma protuberans

Clinical Trials on Dermatofibrosarcoma protuberans at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Dermatofibrosarcoma protuberans

NICE Guidance on Dermatofibrosarcoma protuberans

NHS PRODIGY Guidance

FDA on Dermatofibrosarcoma protuberans

CDC on Dermatofibrosarcoma protuberans

Books

Books on Dermatofibrosarcoma protuberans

News

Dermatofibrosarcoma protuberans in the news

Be alerted to news on Dermatofibrosarcoma protuberans

News trends on Dermatofibrosarcoma protuberans

Commentary

Blogs on Dermatofibrosarcoma protuberans

Definitions

Definitions of Dermatofibrosarcoma protuberans

Patient Resources / Community

Patient resources on Dermatofibrosarcoma protuberans

Discussion groups on Dermatofibrosarcoma protuberans

Patient Handouts on Dermatofibrosarcoma protuberans

Directions to Hospitals Treating Dermatofibrosarcoma protuberans

Risk calculators and risk factors for Dermatofibrosarcoma protuberans

Healthcare Provider Resources

Symptoms of Dermatofibrosarcoma protuberans

Causes & Risk Factors for Dermatofibrosarcoma protuberans

Diagnostic studies for Dermatofibrosarcoma protuberans

Treatment of Dermatofibrosarcoma protuberans

Continuing Medical Education (CME)

CME Programs on Dermatofibrosarcoma protuberans

International

Dermatofibrosarcoma protuberans en Espanol

Dermatofibrosarcoma protuberans en Francais

Business

Dermatofibrosarcoma protuberans in the Marketplace

Patents on Dermatofibrosarcoma protuberans

Experimental / Informatics

List of terms related to Dermatofibrosarcoma protuberans

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Dermatofibrosarcoma protuberans (DFSP) is a rare neoplasm of the dermis layer of the skin, and is classified as a sarcoma. In many respects, the disease behaves as a benign tumor, but in 2-5% of cases it can metastasize, so it should be considered to have malignant potential.

Over 95% of DFSP tumors have the chromosomal translocation t(17;22). The translocation fuses the collagen gene (COL1A1) with the platelet-derived growth factor gene. The fibroblast, the cell of origin of this tumor, expresses the fusion gene in the belief that it is collagen. However the resulting fusion protein is processed into mature platelet-derived growth factor which is a potent growth factor. Fibroblasts contain the receptor for this growth factor. Thus the cell "thinks" it is producing a structural protein, but in fact produces a self-stimulatory growth signal. The cell divides rapidly and a tumor forms.

Treatment is primarily surgical, with chemotherapy and radiation therapy sometimes being used.

There is clinical evidence that imatinib, which inhibits PDGFB, may be effective for tumors positive for the t(17;22) translocation.

External links



WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch

Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools